The presentation of new preclinical data at a prestigious conference like AACR significantly boosts IN8bio's visibility in the biotech and oncology communities. The positive data showing the platform's ability to target cancer cells while sparing healthy tissue highlights the potential of IN8bio's technology to treat a wide range of tumors, including those previously considered 'undruggable'. This could lead to increased investor interest and potentially positive movement in INAB's stock price in the short term.